Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...

Nanexa's atomic layer deposition (ALD) platform PharmaShell® demonstrably improves the pharmacokinetic profile of semaglutide injections.Significantly smoother plasma concentration curve could mitigat ...

Afrezza is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus.

Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic ...

NFL Biosciences SA (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, announces today that it is ...

Japan’s Eisai and US biotech Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing ...

Investing.com -- MannKind Corporation (NASDAQ:MNKD) stock rose 3.5% Monday after the company announced that the U.S. Food and Drug Administration (FDA) approved an update to the prescribing ...

MannKind Corporation (NASDAQ:MNKD) shares gained 3.5% on Monday after the company said the U.S. Food and Drug Administration ...